A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia

EBioMedicine

Volumn 2, Issue 12, 2015, Pages 1987-1995

  Springett, Gregory M ^a   Husain, Kazim ^a   Neuger, Anthony ^b   Centeno, Barbara ^a   Chen, Dung Tsa ^c   Hutchinson, Tai Z ^a   Lush, Richard M ^b   Sebti, Saïd ^d   Malafa, Mokenge P ^a  

^a Department of Gastrointestinal Oncology ^*  (United States)

^b Translational Research Core   (United States)

^c Biostatistics Core   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemoprevention; Pancreatic cancer; Presurgical trial; Tocotrienols; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CASPASE 3; DELTA TOCOTRIENOL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TOCOTRIENOL, DELTA;

ADULT; AGED; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOATING; BODY WEIGHT DISORDER; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOGLYCEMIA; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NAUSEA AND VOMITING; OPEN STUDY; PAIN; PANCREAS ADENOCARCINOMA; PHARMACODYNAMICS; PHARMACOKINETIC ASSAY; PHASE 1 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PRURITUS; RASH; SKIN BRUISING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VERY ELDERLY; WEIGHT REDUCTION; WOUND COMPLICATION; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; TREATMENT OUTCOME; VITAMIN E;

EID: 84958957226     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.11.025     Document Type: Article

References (33)

1. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 2013, 368(9):842-851.
2. Birringer M., EyTina J.H., Salvatore B.A., Neuzil J. Vitamin E analogues as inducers of apoptosis: structure-function relation. Br. J. Cancer 2003, 88(12):1948-1955.
3. Gould M.N., Haag J.D., Kennan W.S., Tanner M.A., Elson C.E. A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. Am. J. Clin. Nutr. 1991, 53(4 Suppl.):1068S-1070S.
4. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362(17):1605-1617.
5. Hodul PJ, Dong Y, Husain K, et al. Vitamin E delta-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. PLoS One 2013; 8(2): e52526.
6. Husain K., Francois R.A., Hutchinson S.Z., et al. Vitamin E delta-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. Pharmacology 2009, 83(3):157-163.
7. Husain K., Francois R.A., Yamauchi T., Perez M., Sebti S.M., Malafa M.P. Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer. Mol. Cancer Ther. 2011, 10(12):2363-2372.
8. Husain K., Centeno B.A., Chen D.T., et al. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E delta-tocotrienol. Carcinogenesis 2013, 34(4):858-863.
9. Husain K., Centeno B.A., Chen D.T., Hingorani S.R., Sebti S.M., Malafa M.P. Vitamin E delta-tocotrienol prolongs survival in the LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prev. Res. (Phila.) 2013, 6(10):1074-1083.
10. Iacobuzio-Donahue C.A. Genetic evolution of pancreatic cancer: lessons learnt from the Pancreatic cancer genome sequencing project. Gut 2012, 61(7):1085-1094.
11. Iacobuzio-Donahue C.A., Velculescu V.E., Wolfgang C.L., Hruban R.H. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 2012, 18(16):4257-4265.
12. Iqbal J., Minhajuddin M., Beg Z.H. Suppression of diethylnitrosamine and 2-acetylaminofluorene-induced hepatocarcinogenesis in rats by tocotrienol-rich fraction isolated from rice bran oil. Eur. J. Cancer Prev. 2004, 13(6):515-520.
13. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
14. Lee I.M., Cook N.R., Gaziano J.M., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294(1):56-65.
15. Ling M.T., Luk S.U., Al-Ejeh F., Khanna K.K. Tocotrienol as a potential anticancer agent. Carcinogenesis 2012, 33(2):233-239.
16. Lippman S.M., Klein E.A., Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301(1):39-51.
17. Nakamura H., Furukawa F., Nishikawa A., et al. Oral toxicity of a tocotrienol preparation in rats. Food Chem. Toxicol. 2001, 39(8):799-805.
18. Ngah W.Z., Jarien Z., San M.M., et al. Effect of tocotrienols on hepatocarcinogenesis induced by 2-acetylaminofluorene in rats. Am. J. Clin. Nutr. 1991, 53(4 Suppl.):1076S-1081S.
19. Qureshi A.A., Bradlow B.A., Brace L., et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995, 30(12):1171-1177.
20. Qureshi A.A., Sami S.A., Salser W.A., Khan F.A. Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis 2002, 161(1):199-207.
21. Rahmat A., Ngah W.Z., Shamaan N.A., Gapor A., Abdul K.K. Long-term administration of tocotrienols and tumor-marker enzyme activities during hepatocarcinogenesis in rats. Nutrition 1993, 9(3):229-232.
22. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22(3):659-661.
23. Siegel R., Naishadham D., Jemal A. Cancer Statistics, 2013. CA Cancer J. Clin. 2013, 63(1):11-30.
24. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2015. CA Cancer J. Clin. 2015, 65(1):5-29.
25. Srivastava J.K., Gupta S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 346(2):447-453.
26. Stan S.D., Singh S.V., Brand R.E. Chemoprevention strategies for pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2010, 7(6):347-356.
27. Sundram K., Khor H.T., Ong A.S., Pathmanathan R. Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz(a)anthracene. Cancer Res. 1989, 49(6):1447-1451.
28. Wada S., Satomi Y., Murakoshi M., Noguchi N., Yoshikawa T., Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 2005, 229(2):181-191.
29. Wu X., Lippman S.M. An intermittent approach for cancer chemoprevention. Nat. Rev. Cancer 2011, 11(12):879-885.
30. Yap S.P., Yuen K.H., Wong J.W. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J. Pharm. Pharmacol. 2001, 53(1):67-71.
31. Yap W.N., Chang P.N., Han H.Y., et al. Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br. J. Cancer 2008, 99(11):1832-1841.
32. Yap W.N., Zaiden N., Luk S.Y., et al. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology 2010, 85(4):248-258.
33. Zaiden N., Yap W.N., Ong S., et al. Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion. J. Atheroscler. Thromb. 2010, 17(10):1019-1032.